Fusion Proteins

News Fusion Proteins

• Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

  Biogen Idec and Swedish Orphan Biovitrum announced the initiation of two global pediatric clinical trials of the companies' long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in hemophilia A and B.rFVIIIFc and rFIXFc are fully-recombinant clotting factors dev more

• Mayo Clinic breast cancer study finds new type of mutation

  Mayo Clinic researchers have discovered a new class of molecular mutation in various forms of breast cancer, a finding that may shed new light on development and growth of different types of breast tumors. Called fusion transcripts, the mutated forms of RNA may also provide a way to identify tumor s more

• Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation

  Swedish Orphan Biovitrum announced that the European Commission has granted orphan drug designation to its long-lasting, fully-recombinant Factor FVIII Fc fusion protein (rFVIIIFc), which is partnered with Biogen Idec. It was recently announced that the companies plan to advance the rFVIIIFc progr more

White papers Fusion Proteins

• Functional Analysis of Side Effects of Transfection Reagents in the Context of Bax-induced Apoptosis
  

  FuGENE® HD Transfection Reagent is well-suited for studying the impact of apoptosis-inducing proteins such as bax. Transfection with FuGENE® HD Transfection Reagent produced only minimal cytotoxic side effects while maintaining a high transfection efficiency. In contrast, cytotoxicity, and off-target effects of the other commercially available transfection reagents tested made it impossible to distinguish the impact of the bax protein from the impact of the transfection reagent itself more

Publications Fusion Proteins

• Mucin-type fusion proteins with blood group A or B determinants on defined O-glycan core chains produced in glycoengineered Chinese hamster ovary cells and their use as immunoa ...

  Assays for quantification, and methods for removal, of anti-A and anti-B antibodies are the key for the success of ABO incompatible organ transplantation programs. In order to produce tools that can be used as substrates in tests for anti-A/anti-B quantification and specificity determination or as more

• The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum–mitochondria tet ...

  DJ-1 was first identified as an oncogene. More recently, mutations in its gene have been found causative for autosomal recessive familial Parkinson disease. Numerous studies support the DJ-1 role in the protection against oxidative stress and maintenance of mitochondria structure; however, the mech more

• {beta}1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

  Antiangiogenic therapies like bevacizumab offer promise for cancer treatment, but acquired resistance, which often includes an aggressive mesenchymal phenotype, can limit the use of these agents. Upregulation of β1 integrin (ITGB1) occurs in some bevacizumab-resistant glioblastomas (BRG) whereby, me more

Market studies Fusion Proteins

• iBio, Inc. (NYSE ) - Financial and Strategic SWOT Analysis Review

  iBio, Inc. (iBio, formerly iBioPharma, Inc.) is a biotechnology company, engaged in the development of vaccines and therapeutic proteins based on its plant-based iBioLaunch platform technology, which is used in the manufacture of biopharmaceuticals. Its products include influenza vaccines, biodefenc more

• Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

  Leading business intelligence provider GBI Research has released its latest research report, “Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017”, which provides insight about immunomodulators sales forecasts until 2017.I Imm more

• Genexine Co., Ltd. (095700) - Financial and Strategic SWOT Analysis Review

  Genexine Co., Ltd. (Genexine) is involved in the research and development of therapeutic vaccines for incurable diseases and next-generation antibody fusion protein drugs such as super-biosimilars. The company's products are used for the therapy areas of anemia, auto-immune diseases, cancer, and dia more

Websites Fusion Proteins